Therapeutic potential of peptide motifs - Part III

Current Pharmaceutical Design

Volumn 16, Issue 9, 2010, Pages 1021-1023

  Hervé, Jean Claude ^a  

^a PBS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; ANTIANDROGEN; ATRIAL NATRIURETIC FACTOR; BRAIN NATRIURETIC PEPTIDE; CYCLIC AMP; CYCLIC GMP; G PROTEIN COUPLED RECEPTOR; MEMBRANE PROTEIN; MORPHINE; NATRIURETIC PEPTIDE TYPE C; NEUROPEPTIDE; OPIATE DERIVATIVE; PHOSPHODIESTERASE; TOLL LIKE RECEPTOR; VASOACTIVE INTESTINAL POLYPEPTIDE; VIRUS GLYCOPROTEIN;

AUTOIMMUNE DISEASE; BIOTECHNOLOGY; BREAST CARCINOMA; CELL MEMBRANE PERMEABILITY; COLON CARCINOMA; EDITORIAL; EFFECTOR CELL; HUMAN; HUMAN GENOME; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IMMUNOMODULATION; INFLAMMATORY DISEASE; INNATE IMMUNITY; KIDNEY CARCINOMA; MORBIDITY; MORTALITY; NONHUMAN; OVARY CARCINOMA; PEPTIDOMICS; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE CARCINOMA; PROTEIN MOTIF; PROTEIN PROTEIN INTERACTION; PROTEOMICS; SENSITIVITY AND SPECIFICITY; UNSPECIFIED SIDE EFFECT;

AMINO ACID MOTIFS; ANIMALS; ANTI-INFECTIVE AGENTS; ANTI-INFLAMMATORY AGENTS; ANTINEOPLASTIC AGENTS; DRUG DISCOVERY; HUMANS; PEPTIDES;

EID: 77950261263     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161210790963797     Document Type: Editorial

References (13)

1. Metz-Boutigue MH, Shooshtarizadeh P, Prevost G, Haikel Y, Chich JF. Antimicrobial peptides present in mammalian skin and gut are multifunctional defence molecules. Curr Pharm Des 2010; 16(9): 1024-1039
2. Brown KC. Peptidic tumor targeting agents: the road from phage display peptide selections to clinical applications. Curr Pharm Des 2010; 16(9): 1040-1054
3. Zhao TX, Martinko AJ, Le VH, Zhao J, Yin H. Development of agents that modulate protein-protein interactions in membranes. Curr Pharm Des 2010; 16(9): 1055-1062
4. Gomariz RP, Gutiérrez-Cañas I, Arranz A, Carrión M, Juarranz Y, Leceta J, et al. Peptides targeting toll-like receptor signalling pathways for novel immune therapeutics. Curr Pharm Des 2010; 16(9): 1063-1080
5. Matijevic T, Pavelić J. Toll-like receptors: cost or benefit for cancer? Curr Pharm Des 2010; 16(9): 1081-1090
6. Snoek SA, Borensztajn KS, van den Wijngaard RM, de Jonge WJ. Neuropeptide receptors in intestinal disease: physiology and therapeutic potential. Curr Pharm Des 2010; 16(9): 1091-1105
7. Gao W. Peptide antagonist of the androgen receptor. Curr Pharm Des 2010; 16(9): 1106-1113
8. Keravis T, Lugnier C. Cyclic nucleotide phosphodiesterases (PDE) and peptide motifs. Curr Pharm Des 2010; 16(9): 1114-1125
9. Janecka A, Perlikowska R, Gach K, Wyrȩbska A, Fichna J. Development of opioid peptide analogues for pain relief. Curr Pharm Des 2010; 16(9): 1126-1135
10. Briand JP, Muller S. Emerging peptide therapeutics for inflammatory autoimmune diseases. Curr Pharm Des 2010; 16(9): 1136-1142
11. Steffen I, Pöhlmann S. Peptide-based inhibitors of the HIV envelope protein and other class I viral fusion proteins. Curr Pharm Des 2010; 16(9): 1143-1158
12. Vesely DL. Metabolic targets of cardiac hormones' therapeutic anti-cancer effects. Curr Pharm Des 2010; 16(9): 1159-1166
13. Ezzat K, EL Andaloussi S, Abdo R, Langel Ü. Peptide-based matrices as drug delivery vehicles. Curr Pharm Des 2010; 16(9): 1167-1178